Centene Corporation (NYSE: CNC) announced today that it has completed the previously announced divestiture of Magellan Specialty Health to Evolent Health, Inc. (Evolent). We are pleased to reach another significant milestone in our ongoing portfolio review and value creation plan,' said Sarah London, Chief Executive Officer of Centene. 'With the close of this transaction, we look forward to launching our national strategic partnership with Evolent and expanding our relationship with Magellan Specialty Health to ensure our members and providers have access to a broad and integrated portfolio of value-based specialty solutions.'